PDCD1 and neoplasm: They have shown that loss of function of the RNA-editing enzyme adenosine deaminase acting on RNA 1 (ADAR1) in tumor cells profoundly sensitizes tumors to immunotherapy and overcomes resistance to PD-1 ICB caused by inactivation of antigen presentation.